D
Domenico Bilancia
Researcher at Seconda Università degli Studi di Napoli
Publications - 71
Citations - 2302
Domenico Bilancia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cetuximab. The author has an hindex of 17, co-authored 64 publications receiving 2161 citations.
Papers
More filters
Journal Article
Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer
Cesare Gridelli,Francesco Perrone,Ciro Gallo,Antonio Rossi,Francesco Scognamiglio,C. Guida,Silvio Monfardini,Giovanni Pietro Ianniello,Vincenza Tinessa,Maria Grazia Caprio,Antonio Santoro,Luigi Maiorino,Massimiliano Santoro,Francovito Piantedosi,L. Brancaccio,Carlo Crispino,S. Cigolari,Maria Di Lanno,Valentina Angelini,Luigi Manzione,Domenico Bilancia,Angelo Dinota,Giuseppe Failla,Rosa Anna Aiello,Paolo Tralongo,F. Figoli,Ludmilla Zuccarino,Tonino Pedicini,Antonio Febbraro,Cesira Zollo,Luciano Frontini,S. Zonato,Giuseppe Azzarello,Orazio Vinante,Federico Castiglione,Gianfranco Porcile,Alessandra Bearz,Roberto Sorio,Maurizio Tonato,S. Darwish,Enzo Veltri,M. D'Aprile,Carlo Curcio,Matteo Vasta,M. Clerici,Gino Luporini,Antonio Farris,Rosario Vincenzo Iaffaioli,Adolfo Favaretto,Giuseppe Gualtieri +49 more
TL;DR: Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall quality of life (QoL) in a multicenter randomized trial that compared vinore lbine treatment with supportive care alone.
Journal ArticleDOI
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
Giuseppe Frasci,Vito Lorusso,N. Panza,Pasquale Comella,G.P. Nicolella,Andrea Bianco,Giuseppe De Cataldis,Annunziato Iannelli,Domenico Bilancia,Mario Belli,Bruno Massidda,Francovito Piantedosi,Giuseppe Comella,Mario De Lena +13 more
TL;DR: In elderly patients with NSCLC, G + V treatment is associated with significantly better survival than is V alone, and a clear delay in symptom and QoL deterioration.
Journal ArticleDOI
Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the southern Italy cooperative oncology group
Pasquale Comella,Giuseppe Frasci,N. Panza,Luigi Manzione,Giuseppe De Cataldis,R. Cioffi,Luigi Maiorino,E. Micillo,Vito Lorusso,Gaetano Di Rienzo,Gianfranco Filippelli,A Lamberti,Michele Di Natale,Domenico Bilancia,G.P. Nicolella,Angelo Di Nota,Giuseppe Comella +16 more
TL;DR: The PGV regimen is associated with a substantial survival gain (MST > 3 months longer) when compared with the PV combination, and the accrual in the PV arm has been stopped (null hypothesis rejected).
Journal ArticleDOI
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Francesco Di Costanzo,Silvia Gasperoni,Luigi Manzione,Giancarlo Bisagni,Roberto Labianca,Stefano Bravi,Enrico Cortesi,Paolo Carlini,Raffaella Bracci,Silverio Tomao,Luca Messerini,Annarosa Arcangeli,Valter Torri,Domenico Bilancia,Irene Floriani,Maurizio Tonato +15 more
TL;DR: The results failed to provide proof of an effect of adjuvant chemotherapy with PELF on overall survival or disease-free survival and the estimated effect of chemotherapy (10% reduction in the hazard of death or relapse) is modest and consistent with the results of meta-analyses of adjUvant chemotherapy without platinum agents.
Journal ArticleDOI
Lapatinib in breast cancer
TL;DR: Improved understanding of the biology of breast cancer and the use of biomarkers for identification of specific subtypes are allowing us to bring patient-specific novel therapies such as lapatinib to the clinic.